Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study.

Morifuji M, Higashi S, Ebihara S, Nagata M

GeroScience24 May 2024Cited by 20 (Europe PMC)

PMID38789831PMCIDPMC11336149DOI10.1007/s11357-024-01204-1PepBankPUB-38789831

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In older adults, NMN did not significantly change stepping test performance versus placebo at either 4 or 12 weeks.
In plain wordsIn older adults, stepping test performance did not differ significantly between NMN and placebo at 4 or 12 weeks.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeStepping test at 4 and 12 weeks
Study
n = 60
Comparator
placebo
Analysis
Primary
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
250 mg/day · oral · 12 weeksAs given in this study (human).
Source sentences
Summary
At primary outcome, at both 4 weeks and 12 weeks, the NMN and placebo groups had no significant differences in a stepping test.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, placebo-controlled, double-blind, parallel-group comparison study, 60 participants were randomly allocated into a placebo group or NMN group.
Summary · context
Members of the NMN group consumed 250 mg/day NMN for 12 weeks.
Report a problemFND-3878983101
02HumanRandomized controlled trialEfficacy outcome
In older adults, NMN reduced 4-m walking time versus placebo after 12 weeks.
In plain wordsIn older adults, NMN shortened walking time versus placebo after 12 weeks.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Decrease4-m walking time
Study
n = 60
Comparator
placebo
Analysis
Secondary
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
250 mg/day · oral · 12 weeksAs given in this study (human).
Source sentences
Summary
At secondary outcomes, after 12 weeks of NMN intake, the NMN group had a significantly shorter 4-m walking time than the placebo group as well as significantly higher blood levels of NAD + and its metabolites.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, placebo-controlled, double-blind, parallel-group comparison study, 60 participants were randomly allocated into a placebo group or NMN group.
Summary · context
Members of the NMN group consumed 250 mg/day NMN for 12 weeks.
Report a problemFND-3878983102
03HumanRandomized controlled trialEfficacy outcome
In older adults, NMN increased blood NAD+ and its metabolites versus placebo after 12 weeks.
In plain wordsIn older adults, NMN increased blood NAD+ and its metabolites versus placebo after 12 weeks.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseBlood NAD+ and its metabolites
Study
n = 60
Comparator
placebo
Analysis
Secondary
Outcome group
Pharmacokinetics · Metabolic and weight
Studied dose
250 mg/day · oral · 12 weeksAs given in this study (human).
Source sentences
Summary
At secondary outcomes, after 12 weeks of NMN intake, the NMN group had a significantly shorter 4-m walking time than the placebo group as well as significantly higher blood levels of NAD + and its metabolites.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, placebo-controlled, double-blind, parallel-group comparison study, 60 participants were randomly allocated into a placebo group or NMN group.
Summary · context
Members of the NMN group consumed 250 mg/day NMN for 12 weeks.
Report a problemFND-3878983103
04HumanRandomized controlled trialEfficacy outcome
In older adults, NMN lowered daytime dysfunction scores versus placebo at 12 weeks.
In plain wordsIn older adults, NMN reduced daytime dysfunction scores versus placebo at 12 weeks.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseDaytime dysfunction score
Study
n = 60
Comparator
placebo
Analysis
Secondary
Outcome group
Sleep · Sleep
Studied dose
250 mg/day · oral · 12 weeksAs given in this study (human).
Source sentences
Summary
The NMN group had improved sleep quality at 12 weeks relative to the placebo group as evidenced by lower scores for "Daytime dysfunction" and "Global PSQI" on the Pittsburgh Sleep Questionnaire.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, placebo-controlled, double-blind, parallel-group comparison study, 60 participants were randomly allocated into a placebo group or NMN group.
Summary · context
Members of the NMN group consumed 250 mg/day NMN for 12 weeks.
Report a problemFND-3878983108
05HumanRandomized controlled trialEfficacy outcome
In older adults, NMN lowered Global PSQI scores versus placebo at 12 weeks.
In plain wordsIn older adults, NMN improved overall sleep scores versus placebo at 12 weeks.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseGlobal PSQI score
Study
n = 60
Comparator
placebo
Analysis
Secondary
Outcome group
Sleep · Sleep
Studied dose
250 mg/day · oral · 12 weeksAs given in this study (human).
Source sentences
Summary
The NMN group had improved sleep quality at 12 weeks relative to the placebo group as evidenced by lower scores for "Daytime dysfunction" and "Global PSQI" on the Pittsburgh Sleep Questionnaire.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, placebo-controlled, double-blind, parallel-group comparison study, 60 participants were randomly allocated into a placebo group or NMN group.
Summary · context
Members of the NMN group consumed 250 mg/day NMN for 12 weeks.
Report a problemFND-3878983109
06HumanRandomized controlled trialSafety outcome
In older adults, no adverse effects related to test substance consumption were observed.
In plain wordsIn older adults, the study reported no adverse effects related to the test substance.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Not applicableTreatment-related adverse effects
Study
n = 60
Outcome group
Adverse events · Whole body
Studied dose
250 mg/day · oral · 12 weeksAs given in this study (human).
Source sentences
Summary
No adverse effects related to test substance consumption were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, placebo-controlled, double-blind, parallel-group comparison study, 60 participants were randomly allocated into a placebo group or NMN group.
Summary · context
Members of the NMN group consumed 250 mg/day NMN for 12 weeks.
Report a problemFND-3878983110
07HumanRandomized controlled trialMechanism
In older adults, changes in walking time correlated negatively with changes in blood NAD at 12 weeks.
In plain wordsIn older adults, greater blood NAD increases were linked to shorter walking times at 12 weeks.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseWalking time association with NAD change
Study
n: not reported in source
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
250 mg/day · oral · 12 weeksAs given in this study (human).
Source sentences
Summary
A significant negative correlation was observed between the change in the 4-m walking time and the change in blood NAD + , N¹-methyl-2-pridone-5-carboxamide (2-PY), and N¹-methyl-4-pridone-3-carboxamide (4-PY) at 12 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, placebo-controlled, double-blind, parallel-group comparison study, 60 participants were randomly allocated into a placebo group or NMN group.
Summary · context
Members of the NMN group consumed 250 mg/day NMN for 12 weeks.
Report a problemFND-3878983105
08HumanRandomized controlled trialMechanism
In older adults, changes in walking time correlated negatively with changes in blood 2-PY at 12 weeks.
In plain wordsIn older adults, greater blood 2-PY increases were linked to shorter walking times at 12 weeks.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseWalking time association with 2-PY change
Study
n: not reported in source
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
250 mg/day · oral · 12 weeksAs given in this study (human).
Source sentences
Summary
A significant negative correlation was observed between the change in the 4-m walking time and the change in blood NAD + , N¹-methyl-2-pridone-5-carboxamide (2-PY), and N¹-methyl-4-pridone-3-carboxamide (4-PY) at 12 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, placebo-controlled, double-blind, parallel-group comparison study, 60 participants were randomly allocated into a placebo group or NMN group.
Summary · context
Members of the NMN group consumed 250 mg/day NMN for 12 weeks.
Report a problemFND-3878983106
09HumanRandomized controlled trialMechanism
In older adults, changes in walking time correlated negatively with changes in blood 4-PY at 12 weeks.
In plain wordsIn older adults, greater blood 4-PY increases were linked to shorter walking times at 12 weeks.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseWalking time association with 4-PY change
Study
n: not reported in source
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
250 mg/day · oral · 12 weeksAs given in this study (human).
Source sentences
Summary
A significant negative correlation was observed between the change in the 4-m walking time and the change in blood NAD + , N¹-methyl-2-pridone-5-carboxamide (2-PY), and N¹-methyl-4-pridone-3-carboxamide (4-PY) at 12 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, placebo-controlled, double-blind, parallel-group comparison study, 60 participants were randomly allocated into a placebo group or NMN group.
Summary · context
Members of the NMN group consumed 250 mg/day NMN for 12 weeks.
Report a problemFND-3878983107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.